

# Evaluating Novel Methods for Endotoxin Testing of Cellular Products – The PACT Experience

Diane Kadidlo  
Operations Manager  
University of Minnesota  
Molecular and Cellular Therapeutics Facility




Production Assistance for Cellular Therapies

# Objectives

- u Regulatory
- u LAL Assay
- u Multicenter study underway comparing 2 commercial endotoxin detection Assays.
- u Preliminary data
- u Points to Consider

# Endotoxin

- u Found in water, food
- u Lipopolysaccharide, integral part of cell wall in gram(-) bacteria.
- u Fever, shock, DIC, leukopenia, leukocytosis, death




# FDA Requirement

*Instructions and Template for CMC  
Reviewers of Human SCT INDs:  
CBER August 2003*

Chemistry, Manufacturing and Control (CMC) section must provide sufficient information to assure proper identification, quality, purity and strength.

# Purity

- u “Products shall be free of extraneous material except that which is unavoidable in the manufacturing process described in the approved biologics license application.” (21 CFR 610.13)
- u Assays:
  - Pyrogenicity/Endotoxin
  - Contaminating cell phenotypes
  - Reagents/antibodies/serum



# Purity - Endotoxin

## u Limulus Amebocyte Lysate (LAL) Test

- Equivalency to Rabbit Pyrogenicity Testing [21 CFR 610.13(b)] for licensure
- Upper limit per FDA 5 EU/kg body weight/dose (intra-theccal lower, 0.2 EU/kg)
- FDA Validation Guideline for LAL December 1987



# LAL

- u Extract derived from circulating amebocytes of horse shoe crab *Limulus polyphemus*
- u Amebocyte + gram(-) bacteria = clot
- u Assays: gel-clot, turbidimetric, chromogenic,



+



Enzymatic Cascade  
Serine Proteases

Ac-Ile-Glu-Ala-Arg·····pNA



Clot /  
Yellow color  
405nm

Reaction time is inversely proportional to amount endo  
Slower rxn time :  $\hat{a}$  Endotoxin  
Faster rxn time :  $\acute{a}$  Endotoxin

# Commercial LAL Detection Assays

Charles River Laboratories  
Endosafe™–Portable Test System



Cambrex Bio Science  
Gel clot, Chromogenic, Kinetic  
Turbidimetric/Chromogenic



# Endotoxin Comparison Study

## Study Aim

- u Compare inhouse endotoxin method (Cambrex BioScience) to portable endotoxin detection system CRL Endosafe™
- u Participants
  - NIH
  - PACT Institutions
    - u Baylor College of Medicine
    - u University of Pittsburgh
    - u University of Minnesota



# Methods

## u CRL Endosafe

- Licensed endpoint kinetic chromogenic method
- Device: incubating chamber, sample pump, 4 LEDs & microprocessor
- 4 well cartridge
  - u 1 sample/cartridge
  - u Sample in duplicate + 2 spiked samples
- Amount of Endotoxin is based upon archived standard curve



## u Cambrex Bio Science:

- Licensed for kinetic chromogenic/turbidimetric method
- Device: incubating plate reader 96 well plate
  - u Standards, blank, sample dilutions, spiked samples
- Amount of Endotoxin is calculated based upon standard curve



# Methods

- u Per FDA 1987 Validation guidance
  - Trained Operator
  - Qualify each new lot of endotoxin
  - Positive product control (PPC) be run with each sample at each dilution (50%-200% or w/in two-fold)
- u Interfering substances
  - pH, albumin, EDTA



Production Assistance for Cellular Therapies

The PACT Group provides education and production assistance to the cell therapy community through contract manufacturing of therapeutic cell products.

## 3 NHLBI -Funded Manufacturing Sites



Baylor College of Medicine's  
Center for Cell and Gene Therapy

University of Minnesota's  
Molecular and Cellular  
Therapeutics



University of Pittsburgh's  
Cancer Center

# Endotoxin

- u Compare inhouse endotoxin method (Cambrex) to Endosafe Charles River Laboratories
- u Study Design
  - Phase 1 –Test known lypholized endotoxin samples
  - Phase 2 - Each site test 12 cell and tissue samples (HCT/Ps) comparing Cambrex to Endosafe method
  - Phase 3 –Each site prepares blinded samples and ship frozen to each of the 3 participating institutions.

# Study Results Phase 1

Sample	Baylor	Baylor	UMN	UMN	Pitt #1	Pitt #1	Pitt #2	Pitt #2	NIH	NIH
Method	Kinet/ Chrom	Endo- Safe	Kinet/ Chrom	Endo- Safe	Gel Clot	Endo- Safe	Gel Clot	Endo- Safe	Kinet/ Turbid	Endo- Safe
Neg ctl	OK	OK	OK	OK	NA	OK	OK	OK	OK	OK
Pos #1	0.3207	0.221	0.266	0.243	0.16	0.143	0.45	0.36	0.231	0.237
Charles River		0.125- 0.5		0.125- 0.5		0.125- 0.5		0.125- 0.5		0.125- 0.5
Pos #2	0.5582	0.393	0.617	0.628	0.41	0.481	0.67	0.476	0.465	0.491
Charles River		0.25- 1.0		0.25- 1.0		0.25- 1.0		0.25- 1.0		0.25- 1.0

# Phase 2

## Endosafe Cell Products

- Cultured T-cell subsets (TH2/TC2) with and w/o Rapamycin
- Cytotoxic T-lymphocytes
- EBV viral vectors
- Ferridex labeled CD34 cells
- Hematopoietic progenitor cells
- Mononuclear cells
- NK Cells
- Peripheral blood stem cells
- SKBR3 cells
- Vero cell line

# Endosafe Results

28 Total Samples

In-House

Neg

Pos

Endosafe

Neg

Pos

28 (100)	0 (0)
0 (0)	0 (0)

\* Positive result > 5EU/mL

# Points to Consider

Observations	Cambrex-Kinetic Chromo. OCL™	CRL Endosafe™
Ease of Use	Moderate – Std curve, multiple dilutions, +/- controls	Very Easy – Sample + spike sample Portable, training easy,
# of Samples/Run	Multiple sample dilutions	1 sample/cartridge
Time	1.5 hour	30 min (+15min for each add'l dilution)
Software/Reports	21 CFR 11 compliant Data locked, audit, pass/fail reports	Text file
Costs	\$16,500 – plate reader, computer, printer \$553 rgt kt ~24 samples/kit \$23/test	\$4000 –plate reader + printer \$330 cartridge pack 10/pack ~\$33/test

# ENDOSAFE

\*\*\*\*\* ENDOSAFE Test Record \*\*\*\*\*

V7.09R 01/10/06

DateTime: ..... 06/02/06 @ 15:44:08  
 Device: ..... 0049  
 OperatorID: ..... SDA  
 Cartridge: ..... Endotoxin  
 Temperature: .. Start: 37.0C End: 37.0C  
 Method: ..... KX-122  
 Cartridge Lot#: ..... 5347144  
 Range: ..... 5-0.05  
 Range Time: ..... Sec: 140-850  
 Onset Time (s): ..... 504 250 660 298  
 Slope: -0.392 ..... Intercept: +2.420  
 Dilution: ..... 20  
 Sample Lot: ..... R060986/1  
 Sample ID: ..... TUFT  
 Sample Value: ..... 2.63 EU/ml  
 Sample CV: ..... 19.0%  
 Spike Value: ..... 0.769 EU/ml  
 Spike CV: ..... 12.4%  
 Spike Recovery: ..... 104%

# Cambrex

Cell Therapy Clinical Laboratory  
 Bio-Whittaker ELx808-I  
 Cambrex Bio Science Walkersville, Inc. - WinKQCL Version 3.00 Page 3 of 3

Analyst ID : SCREW1	BWL LAL Lot No. : FL064E	Exp : 12/13/2008	Time : 4:28:23PM
Initial Qualification Assay	Water Lot No. : FL0290	Exp : 10/26/2008	Date : 9/12/2006
Template : IQ2 SARA	Endotoxin Lot No. : FL0190	Exp : 3/5/2010	BioTek ELx808
Temp : 36.9°C - 37.0°C			S/N 157778

Linear Regression : CORR. = -0.999	SLOPE = -0.228	Y INT. = 3.049
Reader Parameters : Delta t = 150	Meas. Filtr. = 405	Delta mOD = 200
		Reads No. = 40

Curve Parameters			
Parameter	Value	Specification	Status
Correlation Coefficient	-0.999	-1.000 to -0.990	PASS
Slope	-0.228	-0.400 to -0.100	PASS
Y Intercept	3.049	2.500 to 3.500	PASS

Standards				
Concentration	Value	Specification	Status	Note
0.005	1.84%	<10%	PASS	
0.05	0.78%	<10%	PASS	
0.5	0.69%	<10%	PASS	
5.0	5.61%	<10%	PASS	
50	1.17%	<10%	PASS	

( In Notes : ! - Masked Point(s), \* - Point(s) Did Not React, ? - Atypical Point(s), > - High OD)

Accessories Summary				
Name	Lot No.	Manufacturer	Calibration Due	Expiration

Log Summary			
Description	Comments	User ID	Date
Initial Qualification Assay RunDate/Time: 9/12/2006 4:28:23 PM Serial #: 157778		SCREW1	9/12/2006 4:28:23PM
Analyst E-sig applied - Sarah Crew Run Date/Time - Sep 12 2006 4:28PM Number - 0		SCREW1	9/13/2006 3:23:56PM
Reviewer E-sig applied - Darin Sumstad Run Date/Time - Sep 12 2006 4:28PM Number - 0		DARIN S	9/13/2006 3:41:43PM

Performed By : Sarah Crew, CLS (et1-sig) Date/Time : 9/13/2006 3:23:56PM  
 Sarah Crew (SCREW1)

Reviewed By : Darin Sumstad, CLS (et1-sig) Date/Time : 9/13/2006 3:41:43PM  
 Darin Sumstad (DARIN S)

(! = Masked; \*\*\*\* = reaction time > 3900 sec; ???? = atypical; # = Modified; >>>> = High OD)